China’s pharmaceutical sector, a minor player just years ago, has revved up into a global juggernaut faster than a Fuxing high speed train.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
About 5 million people are affected by idiopathic pulmonary fibrosis globally, according to the National Institutes of Health.
Like many other major pharmaceutical companies, AstraZeneca is facing a series of patent cliffs for key treatments in its portfoilio.
A recent trial showed its new 2-for-1 injection was more effective on both illnesses than existing individual shots.
The regulator sees some patents as ploys to keep companies from developing cheaper generic versions of 20 different brand-name drugs.